Hostname: page-component-74656f9884-c52kr Total loading time: 0 Render date: 2026-11-07T10:39:40.728Z Has data issue: false hasContentIssue false

Hypocalcaemia following thyroidectomy for treatment of Graves’ disease: implications for patient management and cost-effectiveness

Published online by Cambridge University Press:  17 June 2011

O R Hughes*
Affiliation:
Department of Otorhinolaryngology, Royal National Throat, Nose and Ear Hospital, London, England, UK Molecular Immunology Unit, Institute of Child Health, University College London, England, UK
D M Scott-Coombes
Affiliation:
Department of Endocrine Surgery, University Hospital of Wales, Cardiff, Wales, UK
*
Address for correspondence: Dr Owain Hughes, Molecular Immunology Unit, Institute of Child Health, University College London, 30 Guilford Street, London WC1N 1EH, UK Fax: +44 (0)207 905 2810 E-mail: mail@owainhughes.com
Rights & Permissions [Opens in a new window]

Abstract

Background:

No consensus exists on optimal treatment for Graves’ disease once anti-thyroid medication fails to induce remission. Total thyroidectomy is a more cost-effective treatment than radioactive iodine or life-long anti-thyroid medication, but hypocalcaemia is an important complication, leading to longer hospital admissions and increased prescription costs. This study aimed to compare the relative risk of hypocalcaemia requiring medical treatment for patients with Graves’ disease.

Methods:

Prospective cohort study of patients undergoing total thyroidectomy for Graves’ disease and for multinodular goitre, calculating serum calcium levels 24-hours post-operatively and prescription rates.

Results:

Mean corrected calcium concentrations 24 hours post-operatively were 2.05 mmol/l for Graves’ disease patients and 2.14 mmol/l for multinodular goitre patients (p = 0.003). Biochemical hypocalcaemia developed in 92 per cent (n = 34) of Graves’ disease patients and 71 per cent (n = 43) of multinodular goitre patients (p = 0.012). Graves’ disease patients were more likely to be prescribed calcium supplementation pre-discharge (p = 0.037).

Conclusion:

Total thyroidectomy for Graves’ disease carries an increased risk of hypocalcaemia at 24 hours, and of calcium supplementation pre-discharge. Graves’ disease patients should be informed of the increased risk of hypocalcaemia associated with total thyroidectomy, and this risk must be factored into future cost-effectiveness analysis.

Information

Type
Main Articles
Copyright
Copyright © JLO (1984) Limited 2011
Figure 0

Table I Standard hypocalcaemia management after thyroid surgery

Figure 1

Fig. 1 Post-operative corrected serum calcium concentrations for patients with Graves’ disease and with benign multinodular goitre, 24 hours after total thyroidectomy.

Figure 2

Fig. 2 Corrected serum calcium concentrations pre-operatively and on day 1 after total thyroidectomy. Box plots with outliers represents means, standard deviations, and maximum and minimum values. MNG = multinodular goitre

Figure 3

Table II Total thyroidectomy patient data, by disease